The magnitude of success will depend on 1) R & R's skills in promoting PPHM to the investment community and 2) the success of the clinical trials, etc. The RS is absolutely necessary to allow PPHM maximum benefit from R & R's analyses and other efforts.
The fact our PPS is tanking on the eve of major positive announcements is very troubling. Theoretically, as more and more people become aware of PPHM’s potential, the PPS and volume should be increasing but instead, the PPS is declining on decreasing volume. BP and the investment community are very reluctant to take new drugs and especially new platforms seriously until proven. Some in-house drugs fail in phase III clinical trials at great financial expense to the company and great emotional expense those involved within the company. This is why biotech stocks take sudden and dramatic leaps after announcements of success and collapse when failure is announced. Hopefully sellers are raising cash and not abandoning a sinking ship.
R & R is a premier IB specializing in biotechs. They would not take on PPHM unless they were fairly certain of its success. They have successfully promoted other biotech companies and will succeed with PPHM. If R & R say we need to RS up to $5, we should heed their advise.
News 
Market Data 
Discover 
AI
